Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Secondary prevention

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    912 result(s) found for: Secondary prevention. Displaying page 1 of 46.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-000131-13 Sponsor Protocol Number: DDD17CRCCXB1 Start Date*: 2017-05-11
    Sponsor Name:KU Leuven
    Full Title: Pharmacokinetics of Celebrex for the prevention/treatment of colorectal cancer: Systemic pharmacokinetics and elimination of Celebrex in healthy volunteers
    Medical condition: Colorectal cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003643-29 Sponsor Protocol Number: VAC31518COV3009 Start Date*: 2020-11-10
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older E...
    Medical condition: Healthy Volunteers, with or without comorbidities (Prevention of SARS-CoV-2-mediated COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) ES (Temporarily Halted) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003220-31 Sponsor Protocol Number: 54463 Start Date*: 2016-06-21
    Sponsor Name:VU medical center, Amsterdam
    Full Title: Low dose aspirin in the Prevention of Recurrent Spontaneous Preterm Labour – the APRIL study
    Medical condition: Prevention of recurrent spontaneous preterm birth
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000956-16 Sponsor Protocol Number: 43907 Start Date*: 2013-07-15
    Sponsor Name:Erasmus Medical Center
    Full Title: Effect of low-dose ketamine on postoperative delirium in patients undergoing noncardiac surgery: a pilot study.
    Medical condition: To investigate the clinical use of Ketamine for the prevention of postoperative delirium in patients undergoing noncardiac surgery.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000619-26 Sponsor Protocol Number: BAY59-7939/16416 Start Date*: 2014-06-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and...
    Medical condition: Long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037439 Pulmonary thrombotic and embolic conditions HLT
    14.1 10047065 - Vascular disorders 10034572 Peripheral embolism and thrombosis HLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) AT (Completed) IT (Completed) ES (Completed) GB (Completed) CZ (Completed) DE (Completed) HU (Completed) DK (Completed) NL (Completed) NO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000970-10 Sponsor Protocol Number: LPS16140 Start Date*: 2020-09-09
    Sponsor Name:Sanofi Aventis Groupe
    Full Title: Phase III, randomized, double blind, parallel groups, clinical trial to evaluate the efficacy and safety of Bacillus clausii versus placebo in the prevention of antibiotic associated diarrhea (AAD)...
    Medical condition: Antibiotic associated diarrhea (AAD) in children
    Disease: Version SOC Term Classification Code Term Level
    21.0 10042613 - Surgical and medical procedures 10064065 Prophylaxis against diarrhoea PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000583-18 Sponsor Protocol Number: 1160.108 Start Date*: 2014-07-25
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years
    Medical condition: Secondary prevention of venous thromboembolism
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FI (Completed) AT (Completed) GR (Completed) IT (Completed) LT (Completed) CZ (Completed) BE (Completed) SK (Completed) SE (Temporarily Halted) BG (Completed) FR (Completed) HU (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001150-27 Sponsor Protocol Number: 2006/01 Start Date*: 2006-09-11
    Sponsor Name:University Hospital Gent
    Full Title: Sandostatin LAR in prevention of Chemotherapy Induced Diarrhea
    Medical condition: Chemo-Therapy Induced Diarrhea
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019947-21 Sponsor Protocol Number: MIGRAPED01 Start Date*: 2011-08-30
    Sponsor Name:CAIBER
    Full Title: Phase III study, multicenter, randomized, double-blind, parallel group measuring the efficacy and safety of flunarizine in the prevention of migraine in the pediatric population.
    Medical condition: Prevention of migraine attacks in pediatric population.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005862-38 Sponsor Protocol Number: Start Date*: 2007-04-05
    Sponsor Name:UCL Mont Godinne
    Full Title: Prevention of Postmenopausal Bone Loss in Osteopenic Women with Alendronate given on a 70 mg Once-every two week Regimen : a 2-year, Double-blind, Placebo-controlled Clinical Trial
    Medical condition: osteopenia and postmenopausal patient
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002476-39 Sponsor Protocol Number: RLX0121 Start Date*: 2021-07-29
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: Prospective study to evaluate the effects of Raloxifene therapy on SARS-CoV-2 immunity after COVID-19 vaccination
    Medical condition: The study will be conducted in non-oncological female patients older than 50 years who have received the first dose of a COVID vaccination, or who have received the full vaccination within 8 weeks...
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001328-21 Sponsor Protocol Number: ABR65448 Start Date*: 2019-01-08
    Sponsor Name:Leiden University Medical Center
    Full Title: Chronotherapy with aspirin for reduction of cardiovascular disease
    Medical condition: The medical condioton to be investigated is recurrent cardiovascular disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000768-27 Sponsor Protocol Number: BAY59-7939/16573 Start Date*: 2015-01-29
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients w...
    Medical condition: Embolic stroke of undetermined source (ESUS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10014498 Embolic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Prematurely Ended) PT (Prematurely Ended) CZ (Completed) BE (Completed) ES (Completed) IT (Prematurely Ended) HU (Completed) FI (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-000954-31 Sponsor Protocol Number: D3560L00006 Start Date*: 2006-05-05
    Sponsor Name:AstraZeneca Oy
    Full Title: Centralised Pan-European Survey on the Undertreatment of Hyperchlesterolemia
    Medical condition: Patients on lipid-lowering pharmacological treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2007-002454-37 Sponsor Protocol Number: RGHT000392 Start Date*: 2007-07-20
    Sponsor Name:The Royal Group Hospitals Trust
    Full Title: Prevention by HMGCoA reductase inhibition of ALI associated with one lung ventilation following oesophagectomy by a Reduction of Pulmonary vascular dysfunction and inflammation (Prevention-HARP)
    Medical condition: Acute lung injury (ALI)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003519-23 Sponsor Protocol Number: D513BC00001 Start Date*: 2014-02-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Pat...
    Medical condition: major cardiovascular events in type 2 diabetes mellitus patients
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10042244 Stroke LLT
    19.1 10007541 - Cardiac disorders 10028596 Myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) SE (Completed) NL (Completed) DE (Completed) IT (Completed) GB (Completed) ES (Completed) NO (Completed) AT (Completed) DK (Completed) BE (Completed) FI (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000904-39 Sponsor Protocol Number: MK-4482-013 Start Date*: 2021-08-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection W...
    Medical condition: Prophylaxis of COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Completed) HU (Completed) BG (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-004620-40 Sponsor Protocol Number: BAY 59-7939/11356 Start Date*: 2006-01-26
    Sponsor Name:Bayer HealthCare AS
    Full Title: RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; controlled, double-blind, randomized study of BAY 59-7939 in the prevention of VTE in subjects undergoing elec...
    Medical condition: Prevention of venous thromboembolism
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012108 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) DE (Completed) DK (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004040-19 Sponsor Protocol Number: 21-ROS-05 Start Date*: 2022-02-09
    Sponsor Name:Guard Therapeutics International AB
    Full Title: A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Adaptive, Parallel Group Clinical Study to Evaluate the Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Foll...
    Medical condition: Cardiac surgery associated acute kidney injury
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10069339 Acute kidney injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001257-51 Sponsor Protocol Number: 220322020 Start Date*: 2020-04-15
    Sponsor Name:Rigshospitalet
    Full Title: The Danish Pre-HCQ Dialysis Study: Hydroxychloroquine for prevention of COVID-19 in dialysis-treated patients with end-stage renal disease - A multicenter parallel-group open randomized clinical...
    Medical condition: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10053983 Corona virus infection PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10038695 Respiratory failure PT
    20.0 100000004857 10023420 Kidney failure chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 08:42:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA